What is Cibus, Inc. (CBUS) stock price today?

Cibus, Inc. (CBUS) is currently trading at $1.55, down 2.52% today.

What is CBUS P/E ratio?

Cibus, Inc.'s P/E ratio is -1.04. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CBUS return on equity (ROE)?

Cibus, Inc.'s return on equity (ROE) is -320.60%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Cibus, Inc.'s market cap?

Cibus, Inc. has a market capitalization of $118.31M.

NASDAQ · Biotechnology

Cibus, Inc. (CBUS) Stock

$1.55 -2.52% NASDAQ: CBUS Healthcare

Valuation

Metric	Value
Price	$1.55
Market Cap	$118.31M
P/E Ratio	-1.04
P/B Ratio	8.87
P/S Ratio	30.03
EPS (TTM)	$0.00
52-Week High	$4.19
52-Week Low	$1.09
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-320.60%
ROA	-31.33%
ROCE	-18.04%
Gross Margin	-1675.00%
Operating Margin	-1675.00%
Net Margin	-23.66%
Debt/Equity	2.21
Current Ratio	0.71

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$26.0M	$0	$2.0M	$4.0M	$4.0M
Operating Profit	$-29.0M	$-22.0M	$-319.0M	$-77.0M	$-67.0M
Net Profit	$-29.0M	$-17.0M	$-268.0M	$-251.0M	$-127.0M
EPS	$-38.96	$-18.36	$-25.95	$-10.83	$-2.78
Op Margin	-112.9%	-14248.4%	-17550.0%	-1805.8%	-1853.9%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$37.0M	$22.0M	$544.0M	$350.0M	$305.0M
Total Liabilities	$23.0M	$15.0M	$206.0M	$252.0M	$283.0M
Cash	$14.0M	$3.0M	$33.0M	$14.0M	$10.0M
Borrowings	$18.0M	$14.0M	$25.0M	$36.0M	$268.0M

Latest News

Cibus (CBUS) Welcomes Landmark EU Crop Breeding Decision Insider Monkey · Jul 14, 2026 Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus GlobeNewswire · Jun 17, 2026 Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation GlobeNewswire · Jun 8, 2026 Cibus, Inc. Q1 2026 Earnings Call Summary Moby · May 15, 2026 Cibus Inc (CBUS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges GuruFocus.com · May 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-19.0M	$-19.0M	$-46.0M	$-58.0M	$-51.0M
Investing Cash Flow	$11.0M	$-3.0M	$51.0M	$-2.0M	$-1.0M
Financing Cash Flow	$-1.0M	$-1.0M	$2.0M	$-2.0M	$0
Net Cash Flow	$-4.0M	$-11.0M	$29.0M	$-18.0M	$-5.0M
Free Cash Flow	$-19.0M	$-21.0M	$-51.0M	$-59.0M	$-51.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.01
EV / EBITDA	-2.42
FCF Yield	-35.49%
Quick Ratio	1.62
Interest Coverage	-2.87
Return 1Y	42.36%
Return 3Y	-89.11%
Return 5Y	-98.90%

Ownership

Insiders Held26.13%

Institutions Held33.63%

Institutions Float Held45.52%

Institutional Holder	Shares	Report Date
FMR, LLC	11,425,929	2026-03-31
Vanguard Capital Management LLC	2,118,496	2026-03-31
Davidson Kempner Capital Management LP	1,527,606	2026-03-31
Vantage Consulting Group, Inc	1,143,949	2025-12-31
Weiss Asset Management Lp	888,124	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACRVAcrivon Therapeutics, Inc.	$1.91	+2.14%	-1.12	$81.75M	0.00%
BMEABiomea Fusion, Inc.	$1.42	+3.65%	-2.56	$102.67M	0.00%
CAMPCAMP4 Therapeutics Corporation	$3.77	+1.89%	-1.66	$236.58M	0.00%
IMUXImmunic, Inc.	$8.19	+8.33%	-1.59	$111.56M	0.00%
MNOVMediciNova, Inc.	$1.52	-1.30%	-8.20	$74.82M	0.00%

About Cibus, Inc.

Cibus, Inc. is led by CEO Peter R. Beetham, employs 157 people, headquartered in US, publicly traded since 2017.

Cibus, Inc. (CBUS) stock trades at $1.55 with a market capitalization of $118.31M. The stock is valued at a price-to-earnings (P/E) ratio of -1.04, price-to-book of 8.87, price-to-sales of 30.03. Over the past 52 weeks the stock has ranged between $1.09 and $4.19, and currently trades 63.0% below its 52-week high.

On profitability, Cibus, Inc. generates a return on equity (ROE) of -320.60%, return on capital employed of -18.04%, an operating margin of -1675.00%, a net profit margin of -23.66%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides